From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA approves Tetraphase's antibiotic Xerava

from BioPharma Dive

Big pharmas backed away from antibiotics in recent years, as the challenge of counteracting "superbugs" provided a tougher path to market. Earlier this year, for example, Allergan said it will sell off its infectious disease unit, which includes antibiotics. AstraZeneca sold its antibiotics portfolio in 2016, and Novartis reportedly exited the space earlier this year. That's left much of the space to smaller biotechs like Tetraphase. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063